Key Patent Issued on Qantu's QT-0101 Adjuvant LEWISVILLE, Texas, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Qantu Therapeutics, Inc. announces the issuance of United States patent 10,195,257 titled “Vaccine Formulations Comprising Quillaja...

Qantu Publishes Study Analyzing the Situation of Alzheimer's Disease Vaccines Development LEWISVILLE, TX--(Marketwired - April 20, 2016) - Qantu Therapeutics, Inc. announces the publication of the article "A retrospective analysis of the Alzheimer's disease vaccine progress The...